19 results about "Chromane" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to a synthetic method and application of a cyclobutane and chroman skeleton molecular compound, which is a method for synthesizing a cyclobutane and chroman skeleton molecular compound through a triplet-triplet energy transfer mechanism by using a blue light excitation photocatalyst under a mild condition. The invention discloses a method for constructing a cyclobutane and chroman skeleton molecular compound by efficiently, highly regionally and stereoselectively catalyzing intramolecular [2 + 2] cycloaddition of a 2H-chromene compound, and further explores the application potential of the cyclobutane and chroman skeleton molecular compound in research and development of anti-glioma drugs. The obtained compound can specifically and effectively kill glioma stem cells, and a new lead compound and thought are provided for research and development of anti-glioma drugs.

The invention relates to a purple jade extract as well as a preparation method and application thereof, and belongs to the field of plant extracts. According to the purple jade extract as well as the preparation method and the application thereof provided by the invention, the extraction of flavonoid substances rich in a dendrobium devonianum variety'purple jade 'is completed for the first time, the extract with the total flavonoid content of more than or equal to 17% is obtained, and the condition that the dendrobium devonianum variety'purple jade' contains two substances, namely rutin and vicenin-2, is determined through qualitative and quantitative analysis. Through verification, the purple jade extract disclosed by the invention has a good antioxidant function, and the total antioxidant capacity of the purple jade extract is close to that of a water-soluble vitamin E analogue Trolox (6-hydroxy-2, 5, 7, 8-tetramethylchromane-2-carboxylic acid) with the equivalent weight of 4mM. According to the purple jade extract as well as the preparation method and the application thereof, a scientific basis is provided for application of purple jade in related directions, and the purple jade extract can be used as an intermediate for development of purple jade series products (such as in the fields of medicine, food, daily necessity development and the like).

Described herein are compounds of Formula (I) and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).

Disclosed are chromane compounds, analogs thereof, and methods of their synthesis and use. The compounds may be synthesized by methods involving reductive annulations of arylidene malonates with unsaturated electrophiles using photoredox / Lewis acid cooperative catalysis. The compounds may be formulated in a pharmaceutical composition for treating one of the aforementioned diseases or disorders.

This invention relates to the field of asymmetric catalytic hydrogenation, specifically to a method for preparing chiral chromone or chromane carboxylic acid compounds. The method involves preparing a chiral catalyst from a nickel compound and ligands. By controlling the combination of the nickel compound-ligand-solvent, enantioselective hydrogenation of the conjugated C=C bonds of the substrate chromone carboxylic acid compound is achieved, yielding the semi-reduced product chiral chromone carboxylic acid; or, further, the carbonyl group is reduced, and carbonyl reduction and dehydroxylation reactions are carried out at room temperature under trifluoroacetic acid and triethylsilane conditions to obtain the fully reduced product chiral chromane carboxylic acid. The catalytic system of this invention is simple to construct, and the selectivity can be controlled by the solvent system. It maintains high conversion and excellent enantioselectivity even under high S / C conditions, making it suitable for the efficient preparation of chiral chromone / chromane skeletal carboxylic acid compounds.

Disclosed in the present invention are a polymorph of a benzo[c]chroman compound, a preparation method therefor and use thereof. The present invention particularly provides a polymorph of a compound represented by formula I, a preparation method therefor and use thereof. The compound represented by formula I is used as a cathepsin C inhibitor, and a crystalline form of the compound and a pharmaceutical composition comprising the crystalline form can be used for treating asthma, obstructive pulmonary diseases, bronchiectasis, ANCA-related vasculitis, psoriasis, α1-antitrypsin deficiency, lupus nephritis, diabetes, inflammatory bowel diseases, rheumatic arthritis, rhinosinusitis, hidradenitis suppurativa or cancers.

Disclosed are polymorphs of benzo[c]chromane compounds, and preparation methods and uses thereof, and specifically provided are polymorphs of a compound shown in formula I, and preparation methods and uses thereof. The compound shown in formula I is a cathepsin C inhibitor, and the crystal form and the pharmaceutical composition containing the crystal form can be used for treating asthma, obstructive pulmonary disease, bronchiectasis, ANCA-associated vasculitis, psoriasis, alpha 1-antitrypsin deficiency, lupus nephritis, diabetes, inflammatory bowel disease, rheumatoid arthritis, sinusitis, hidradenitis suppurativa or cancer.

The present invention relates to the field of herbicides useful for controlling the proliferation of unwanted plants. In particular, the invention relates to the use of at least one compound derived from chromene or chromane as a herbicidal agent, to a phytotoxic composition comprising said compound, and to a method for treating and / or controlling plants using such a compound. Figure to be published: none

This invention pertains to organic synthesis and medicinal chemistry, specifically relating to a 4-chromone-cyclohexane spirocyclic trimer compound, its preparation method, and its applications. The 4-chromone-cyclohexane spirocyclic trimer compound has the structure shown in Formula I, II, III, or IV, or stereoisomers of the structures shown in Formulas I to IV. This invention also provides a method for preparing this compound, using 2-hydroxyacetophenone or its derivatives as a starting material, reacting it with dihalomethane in the presence of a base and additives to construct a spirocyclic trimer skeleton in one step. The compound of this invention can inhibit PPM1E and PPM1F protein phosphatases with high activity and high selectivity, achieving nanomolar inhibitory activity against PPM1E and sub-enzyme selectivity exceeding 100-fold. The compound of this invention can be used to prepare drugs for cancers associated with PPM1E / PPM1F overexpression.

Disclosed herein are methods for achieving palladium-catalyzed cyclization C(sp 3 )‑H / C(sp 2 )‑H coupling reactions using natural, free carboxylic acids as directing groups, amino acid ligands, and oxidizing agents. The methods can be used to synthesize a range of biologically important parent nuclei, including tetralins, chromananes, and indanes.

Methods, compositions, and kits are provided for synthesizing bioactive chromane, the method including: constructing a tertiary ether stereocenter enantioselectively by catalyzed alkynylation of a substituted chromenone to obtain a chromanone; reducing alkyne and ketone in the chromanone to obtain a chroman; and converting ester to methyl group thereby obtaining chromane.

Provided are monobactam compounds of Formula (I), and pharmaceutically acceptable salts thereof. Also provided are compositions which comprise a monobactam compound of Formula (I) or a pharmaceutically acceptable salt therof, and a pharmaceutically acceptable carrier. Further provided are methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

A pharmaceutically acceptable salt of a benzo[c]chroman compound and a polymorphic form and use of the pharmaceutically acceptable salt. The pharmaceutically acceptable salt is selected from hydrochloride, methanesulfonate, phosphate, L-tartrate, maleate, p-toluenesulfonate, sulfate, fumarate, succinate, citrate, malate, and hydrobromide. The pharmaceutically acceptable salt and the polymorphic form thereof improve the bioavailability and the stability, and as a cathepsin C inhibitor, can be used for treating asthma, obstructive pulmonary disease, bronchiectasis, ANCA-associated vasculitis, psoriasis, α1-antitrypsin deficiency, lupus nephritis, diabetes, inflammatory bowel disease, rheumatoid arthritis, sinusitis, hidradenitis suppurativa, or cancer.

The invention belongs to the technical field of organic synthesis, and relates to a synthetic method of chroman-5-amine. The molecular structural formula of the chroman-5-amine is shown as a formula 1. The synthesis method of the chroman-5-amine comprises the following steps: by taking methyl 4-bromo-3-hydroxybenzoate as a raw material, carrying out six-step reaction of substitution, cyclization, elimination, hydrolysis, amination and Boc group removal to synthesize the compound chroman-5-amine. The synthesis method is mild in condition, simple and efficient.

The present disclosure relates to compounds and their uses for treating cancers, including breast cancer, in a subject in need of treatment, comprising administering at least one compound disclosed herein.

The present disclosure relates to compounds and their uses for treating cancers, including breast cancer, in a subject in need of treatment, comprising administering at least one compound disclosed herein.

Herbicides useful for controlling the proliferation of undesired plants. In particular, the use of at least one compound derived from chromene or chromane as a herbicidal agent, a phytotoxic composition including the at least one compound derived from chromene or chromane, as well as a method for treating and / or controlling plants using the at least one compound derived from chromene or chromane.

Provided are a compound of Formula 1 having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.:

Compounds and a method of treating a retinal disease that leads to photoreceptor loss or outer-retina degeneration, including administering compound of the formula (I)or a pharmaceutically acceptable salt, a racemic mixture, a corresponding enantiomer or, if applicable, a corresponding diastereomer thereof, wherein: A is selected from 5-oxazolyl, pyridine-4-yl, triazolyl, oxadiazolyl, imidazolyl and 2-methyloxazol-5-yl residue, R1, and R12 are independently selected from hydrogen, fluoro, chloro, methoxy, trifluoromethyl, methyl and difluoromethoxy, B is selected from a residue of formulae (II)-(IX)wherein,“*” denotes the point of attachment to the remainder of the molecule, andR2, R3, R4, R5, R2I, R3I, R4I, R5I, R2II, R3II, R4II, R5II, R2III, R3III, R4III, R5III, R2IV, R3IV, R4IV, R5IV, R2V, R3V, R4V, R5V, R2VI, R3VI, R4VI, R5VI, R2VII, R3VII, R4VII, and R5VII are independently selected from hydrogen, linear or branched alkyl having 1-3 carbon atoms, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, 2,2,2-trifluoromethyl and difluoromethoxy.